
Conference Coverage
Latest Content

How Effective and Safe Are GLP-1s for Weight Loss?

MSM in Australia Had Multiple Preferences for Mode of PrEP

FDA Approves Plozasiran to Reduce Triglycerides in Familial Chylomicronemia Syndrome

Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line

Ultraprocessed Foods Linked to Higher Risk of Early-Onset Colorectal Adenomas

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Lower-income countries rarely gain timely access to FDA-approved drugs tested in their populations, highlighting major global and ethical disparities.

Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine.

Targeted financing, clinician recruitment, and telehealth expansion are needed to improve rural primary care.

Guselkumab significantly inhibited structural joint damage and improved symptoms in active PsA through 48 weeks.

Infectious disease was hit hardest by funding cuts to NIH grant for clinical trials that did not align with the Trump administration's priorities.

Cuts to Medicaid could spell trouble for pediatric health, as millions of children rely on Medicaid to cover their hospital expenses.

Research challenges age cut-offs in AML treatment, advocating for flexible, individualized approaches based on continuous age assessment.

The race of a telephonic care manager did not impact closure rates for gaps in care among Black Medicare Advantage beneficiaries.

Patients 65 years and older had improved overall and cancer-specific survival after undergoing chemoradiotherapy for stage 2 NSCLC.

Topline results find that single-tablet regimen of bictegravir/lenacapavir had noninferior efficacy when patients switched from multitablet regimens in HIV.































































